State Street Corp. Updates Passive Stake in Kymera Therapeutics
Ticker: KYMR · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1815442
| Field | Detail |
|---|---|
| Company | Kymera Therapeutics, Inc. (KYMR) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still holds Kymera stock, showing continued institutional backing.**
AI Summary
State Street Corporation, a major financial institution, filed an amended Schedule 13G/A on January 23, 2024, indicating its ownership of Kymera Therapeutics, Inc. common stock as of December 31, 2023. This filing is an update to their previous disclosures, confirming their continued passive investment in Kymera. For investors, this means a significant institutional holder maintains its position, which can signal confidence in the company's long-term prospects.
Why It Matters
This filing confirms State Street Corporation's continued passive investment in Kymera Therapeutics, signaling institutional confidence in the company's stock.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor, indicating a passive stake and not a significant change in investment strategy.
Analyst Insight
Investors should note that a major institutional investor, State Street Corporation, continues to hold a passive stake in Kymera Therapeutics, Inc. This indicates a stable, long-term institutional presence, which can be a positive signal for the company's stability, but does not suggest any immediate catalysts or changes in strategy.
Key Numbers
- 20240123 — Filing Date (The date the SC 13G/A was filed with the SEC.)
- 20231231 — Date of Event (The date as of which the ownership information is being reported.)
- 04-2456637 — IRS Identification No. (State Street Corporation's IRS identification number.)
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Kymera Therapeutics, Inc. (company) — the subject company whose common stock is being reported
- 0000093751-24-000096 (dollar_amount) — accession number for the filing
- 0001815442 (dollar_amount) — Central Index Key (CIK) for Kymera Therapeutics, Inc.
- 0000093751 (dollar_amount) — Central Index Key (CIK) for State Street Corporation
- 501575104 (dollar_amount) — CUSIP number for Kymera Therapeutics, Inc. common stock
Forward-Looking Statements
- State Street Corporation will maintain its passive investment in Kymera Therapeutics, Inc. for the foreseeable future. (State Street Corporation) — high confidence, target: 2025-01-23
- Kymera Therapeutics, Inc. will continue to be a focus for institutional investors in the biotechnology sector. (Kymera Therapeutics, Inc.) — medium confidence, target: 2024-12-31
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, indicating an update to a passive ownership stake in a company, as stated in the 'FORM TYPE: SC 13G/A' section.
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, as clearly identified under '1. NAME OF REPORTING PERSON: STATE STREET CORPORATION' on page 2 of the filing.
What is the subject company whose shares are being reported?
The subject company is KYMERA THERAPEUTICS INC, as stated under 'NAME OF ISSUER' on the cover page of the filing.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the common stock of Kymera Therapeutics Inc. is 501575104, as listed under 'CUSIP NUMBER' on the cover page and 'CUSIP NO:501575104' on page 2.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as indicated by '12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)' on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Kymera Therapeutics, Inc. (KYMR).